MET Exon 14 Skipping Mutations in Lung Cancer: Clinical–Pathological Characteristics and Immune Microenvironment
MET exon 14 skipping mutations have emerged as significant driver alterations in non-small-cell lung cancer (NSCLC), contributing to tumor progression. This study examines the immune microenvironment in NSCLC patients with these mutations and its prognostic implications. We performed multiplex immun...
Saved in:
| Main Authors: | Qianqian Xue, Yue Wang, Qiang Zheng, Ziling Huang, Yicong Lin, Yan Jin, Yuan Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-07-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/7/403 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trialResearch in context
by: Yang Xia, et al.
Published: (2025-03-01) -
MET exon 14 skipping mutations in non-small-cell lung cancer a 3 years screening experience
by: R. Ben Dhiab, et al.
Published: (2025-06-01) -
The Landscape of MET Exon 14 Skipping Mutations in Patients With Lung Cancer Identified by Next-Generation Sequencing
by: Jia Liao, MD, et al.
Published: (2025-07-01) -
Antisense‐mediated exon skipping: a therapeutic strategy for titin‐based dilated cardiomyopathy
by: Michael Gramlich, et al.
Published: (2015-03-01) -
Lung Adenocarcinoma Exhibiting Thanatosomes (Hyaline Bodies), Cytoplasmic Clearing, and Nuclear Pleomorphism, with a <i>KRAS</i> Mutation
by: Mitsuhiro Tachibana, et al.
Published: (2025-04-01)